Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-04
2006-04-04
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S438000, C548S252000, C549S079000
Reexamination Certificate
active
07022726
ABSTRACT:
The invention relates to the use of derivatives of E-type prostaglandins as EP2agonists, in general, and, in particular as ocular hypotensives. The PGE derivatives used in accordance with the invention are represented by the following formula I:wherein the hatched segment represents an α bonds, the solid triangle represents a β bond, the wavy segments represent α or β bond, dashed lines represent a double bond or a single bond, X is selected from the group consisting of hydrogen and halogen radicals, R3is heteroaryl or a substituted heteroaryl radical, R1and R2are independently selected from the group consisting of hydrogen or a lower alkyl radical having up to six carbon atoms, or a lower acyl radical having up to six carbon atoms, R is selected from the group consisting of CO2R4, CONR42, CH2OR4, CONR4SO2R4, P(O)(OR4) andwherein R4is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms and n is 0 or an integer of from 1 to 4.
REFERENCES:
patent: 4994274 (1991-02-01), Chan et al.
patent: 5028624 (1991-07-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
patent: 5446041 (1995-08-01), Chan et al.
patent: 6248783 (2001-06-01), Burk et al.
patent: 6376533 (2002-04-01), Burk et al.
patent: 2001-139544 (2001-05-01), None
patent: 96/36599 (1996-11-01), None
patent: 02/09717 (2002-02-01), None
Bito, L.Z.,Biological Protection with Prostaglandins, Cohen, M.M., ed., Boca Raton, Fla, CRC Press Inc., 1985, pp. 231-252.
Bito, L.Z.,Applied Pharmacology in the Medical Treatment of Glaucomas, Drance, S.M. and Neufeld, A.H. eds, New York, Grune & Stratton, 1984, pp. 477-505.
Nilsson et al, Invest.Ophthalmol. Vis. Sci. (suppl), 284 (1987).
Bito, L.Z.,Arch. Ophthalmol. 105, 1036 (1987).
Siebold et al,Prodrug5 3 1989.
Burk Robert M.
Holoboski Mark
Posner Mari F.
Allergan Inc.
Baran Robert J.
Donovan Stephen
Saeed Kamal
Voet Martin A.
LandOfFree
ω-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ω-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ω-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3549639